Topical Co-administration of Zoledronate with Recombinant Human Bone Morphogenetic Protein-2 Can Induce and Maintain Bone Formation in the Bone Marrow Environment

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2021 Jan 21

PMID 33472600

Citations 1

Authors

Hideki Ueyama

Yoichi Ohta

Yuuki Imai

Akinobu Suzuki

Ryo Sugama

Yukihide Minoda

Kunio Takaoka

Hiroaki Nakamura

Affiliations

Soon will be listed here.

Abstract

Background: Bone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow environment, the maintenance of new bone formation is difficult owing to vigorous bone resorption. This is because BMPs stimulate the differentiation of not only osteoblast precursor cells but also osteoclast precursor cells. The present study aimed to induce and maintain new bone formation using the topical co-administration of recombinant human BMP-2 (rh-BMP-2) and zoledronate (ZOL) on beta-tricalcium phosphate (β-TCP) composite.

Methods: β-TCP columns were impregnated with both rh-BMP-2 (30 µg) and ZOL (5 µg), rh-BMP-2 alone, or ZOL alone, and implanted into the left femur canal of New Zealand white rabbits (n = 56). The implanted β-TCP columns were harvested and evaluated at 3 and 6 weeks after implantation. These harvested β-TCP columns were evaluated radiologically using plane radiograph, and histologically using haematoxylin/eosin (H&E) and Masson's trichrome (MT) staining. In addition, micro-computed tomography (CT) was performed for qualitative analysis of bone formation in each group (n = 7).

Results: Tissue sections stained with H&E and MT dyes revealed that new bone formation inside the β-TCP composite was significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). Micro-CT data also demonstrated that the bone volume and the bone mineral density inside the β-TCP columns were significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05).

Conclusions: The topical co-administration of both rh-BMP-2 and ZOL on β-TCP composite promoted and maintained newly formed bone structure in the bone marrow environment.

Citing Articles

The Role of BMP Signaling in Osteoclast Regulation.

Heubel B, Nohe A J Dev Biol. 2021; 9(3).

PMID: 34203252 PMC: 8293073. DOI: 10.3390/jdb9030024.

References

Miller P, Jamal S, Evenepoel P, Eastell R, Boonen S . Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res. 2013; 28(10):2049-59. DOI: 10.1002/jbmr.2058. View

Amanat N, McDonald M, Godfrey C, Bilston L, Little D . Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007; 22(6):867-76. DOI: 10.1359/jbmr.070318. View

Wu M, Chen G, Li Y . TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016; 4:16009. PMC: 4985055. DOI: 10.1038/boneres.2016.9. View

Murakami S, Miyaji H, Nishida E, Kawamoto K, Miyata S, Takita H . Dose effects of beta-tricalcium phosphate nanoparticles on biocompatibility and bone conductive ability of three-dimensional collagen scaffolds. Dent Mater J. 2017; 36(5):573-583. DOI: 10.4012/dmj.2016-295. View

Huang X, Huang L, Cheng Y, Li F, Zhou Q, Wu C . Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019; 44(2):582-592. PMC: 6605660. DOI: 10.3892/ijmm.2019.4207. View

Fujioka-Kobayashi M, Kobayashi E, Schaller B, Mottini M, Miron R, Saulacic N . Effect of recombinant human bone morphogenic protein 9 (rhBMP9) loaded onto bone grafts versus barrier membranes on new bone formation in a rabbit calvarial defect model. J Biomed Mater Res A. 2017; 105(10):2655-2661. DOI: 10.1002/jbm.a.36125. View

Strickland A, Cavanaugh D, Leatherwood W, Raynor J, Brown A, Weinhold P . Effect of local zoledronic acid administration in a rat model of posterolateral spinal fusion. J Orthop. 2019; 17:101-105. PMC: 6919377. DOI: 10.1016/j.jor.2019.08.021. View

Watanabe S, Takabatake K, Tsujigiwa H, Watanabe T, Tokuyama E, Ito S . Efficacy of Honeycomb TCP-induced Microenvironment on Bone Tissue Regeneration in Craniofacial Area. Int J Med Sci. 2016; 13(6):466-76. PMC: 4893562. DOI: 10.7150/ijms.15560. View

Yu W, Sun T, Qi C, Ding Z, Zhao H, Zhao S . Evaluation of zinc-doped mesoporous hydroxyapatite microspheres for the construction of a novel biomimetic scaffold optimized for bone augmentation. Int J Nanomedicine. 2017; 12:2293-2306. PMC: 5373825. DOI: 10.2147/IJN.S126505. View

10.

Ogose A, Hotta T, Hatano H, Kawashima H, Tokunaga K, Endo N . Histological examination of beta-tricalcium phosphate graft in human femur. J Biomed Mater Res. 2002; 63(5):601-4. DOI: 10.1002/jbm.10380. View

11.

Lim H, Mercado-Pagan A, Yun K, Kang S, Choi T, Bishop J . The effect of rhBMP-2 and PRP delivery by biodegradable β-tricalcium phosphate scaffolds on new bone formation in a non-through rabbit cranial defect model. J Mater Sci Mater Med. 2013; 24(8):1895-903. PMC: 4012921. DOI: 10.1007/s10856-013-4939-9. View

12.

Chen W, Jingushi S, Hirata G, Matsumoto Y, Iwamoto Y . Intramuscular bone induction by the simultaneous administration of recombinant human bone morphogenetic protein 2 and bisphosphonate for autobone graft. Tissue Eng. 2005; 10(11-12):1652-61. DOI: 10.1089/ten.2004.10.1652. View

13.

Li M, Wan P, Wang W, Yang K, Zhang Y, Han Y . Regulation of osteogenesis and osteoclastogenesis by zoledronic acid loaded on biodegradable magnesium-strontium alloy. Sci Rep. 2019; 9(1):933. PMC: 6353919. DOI: 10.1038/s41598-018-37091-8. View

14.

Ichikawa K, Ohta Y, Mamoto K, Mizokawa S, Minoda Y, Imai Y . Local co-application of zoledronate promotes long-term maintenance of newly formed bone induced by recombinant human bone morphogenetic protein 2. Biochem Biophys Res Commun. 2016; 480(3):314-320. DOI: 10.1016/j.bbrc.2016.10.034. View

15.

Little D, Ramachandran M, Schindeler A . The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br. 2007; 89(4):425-33. DOI: 10.1302/0301-620X.89B4.18301. View

16.

Dimar 2nd J, Glassman S, Kenneth Burkus J, Pryor P, Hardacker J, Carreon L . Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am. 2009; 91(6):1377-86. DOI: 10.2106/JBJS.H.00200. View

17.

Chou J, Hao J, Kuroda S, Ben-Nissan B, Milthopre B, Otsuka M . Bone regeneration of calvarial defect using marine calcareous-derived beta-tricalcium phosphate macrospheres. J Tissue Eng. 2014; 5:2041731414523441. PMC: 4012694. DOI: 10.1177/2041731414523441. View

18.

Okamoto M, Murai J, Yoshikawa H, Tsumaki N . Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res. 2006; 21(7):1022-33. DOI: 10.1359/jbmr.060411. View

19.

Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M . Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone. 2000; 27(4):479-86. DOI: 10.1016/s8756-3282(00)00358-6. View

20.

Yano K, Hoshino M, Ohta Y, Manaka T, Naka Y, Imai Y . Osteoinductive capacity and heat stability of recombinant human bone morphogenetic protein-2 produced by Escherichia coli and dimerized by biochemical processing. J Bone Miner Metab. 2009; 27(3):355-63. DOI: 10.1007/s00774-009-0040-3. View